In short
Clinical trials investigating ARGININE GLUTAMATE are studying its use in people on chronic hemodialysis, with a focus on muscle protein turnover and blood flow effects. The main aim is to assess how the treatment affects muscle protein synthesis and hemodynamic responses in a small Phase 3 study.
Key points
- Clinical trials investigating ARGININE GLUTAMATE are focused on people with chronic hemodialysis. The main study is a Phase 3 interventional trial called LOTUS, with 20 planned participants. Researchers are looking at muscle protein turnover, especially the rate of muscle protein synthesis, and also at hemodynamic effects. The main endpoint is the difference in myofibrillar fractional synthetic rate after one week of treatment with IDPN versus control. This means the trial is measuring how quickly muscle proteins are being made and comparing treatment with a control condition.
Trial overview
The available trial data describe one interventional study, LOTUS, investigating ARGININE GLUTAMATE in the setting of chronic hemodialysis. The study is looking at muscle protein turnover, which means how the body builds and breaks down muscle protein over time.
The brief summary says the study is designed to see the effect of IDPN on muscle protein synthesis in chronic hemodialysis patients and to characterize the hemodynamic effects of IDPN.
Study design and phase
LOTUS is listed as a Phase 3 study, which means it is a later-stage clinical trial. It is also described as an interventional study, so researchers are giving a treatment and then measuring its effects.
The trial status is Authorised, and the planned enrollment is 20 participants. The intervention is listed as a drug combination given parenterally, which means by a route that does not use the digestive tract.
Who is being studied
The target population is people receiving hemodialysis. The trial data do not provide additional inclusion or exclusion rules, so the only clearly stated group is chronic hemodialysis patients.
This focus matters because the study is not looking at a general healthy population; it is aimed at a specific patient group with kidney failure treated by dialysis.
What is being measured
The main endpoint is the difference in myofibrillar fractional synthetic rate during one week of treatment with IDPN versus control. This is a research measure of how quickly muscle fibers are making new protein.
The study also aims to describe the hemodynamic effects of IDPN, meaning changes related to blood flow and circulation. Together, these outcomes show that the trial is looking at both muscle-related and circulation-related effects in the dialysis setting.
Trial summary
In the trial record, the study title is LOTUS. The condition fields list muscle protein turnover and hemodialysis, and the brief summary explains that the goal is to study muscle protein synthesis and hemodynamic effects in chronic hemodialysis patients.
The single available study is small, with 20 planned participants, and it is already authorised. Based on the source data, this trial is mainly a focused research study in a specific dialysis population rather than a broad study across many diseases.